Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat.

Du TQ, Ou Y, Liu RJ, Feng Y, Li Y, Chen G, Wu X

Open source

DOI
10.1111/jcmm.71330
Published
2026 Aug
Container
Journal of cellular and molecular medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/jcmm.71330,
  title = {Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat.},
  author = {Du TQ and Ou Y and Liu RJ and Feng Y and Li Y and Chen G and Wu X},
  year = {2026},
  journal = {Journal of cellular and molecular medicine},
  doi = {10.1111/jcmm.71330},
  url = {https://doi.org/10.1111/jcmm.71330}
}

RIS

TY  - JOUR
TI  - Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat.
AU  - Du TQ
AU  - Ou Y
AU  - Liu RJ
AU  - Feng Y
AU  - Li Y
AU  - Chen G
AU  - Wu X
PY  - 2026
JO  - Journal of cellular and molecular medicine
DO  - 10.1111/jcmm.71330
UR  - https://doi.org/10.1111/jcmm.71330
ER  - 

APA

TQ, D., Y, O., RJ, L., Y, F., Y, L., G, C., & X, W. (2026). Unveiling the New Trick for Epigenetic Drug: Radiation Enhancement of Prostate Cancer by the EZH2 Inhibitor Tazemetostat.. Journal of cellular and molecular medicine. https://doi.org/10.1111/jcmm.71330

Source records